17. The use of claim 15, wherein the cancer is selected from glioma (glioblastoma), acute myelogenous leukemia, melanoma, non-small cell lung cancer (NSCLC), cholangiocarcinomas, chondrosarcoma, myelodysplastic syndromes (MDS), myeloproliferative neoplasm (MPN), and colon cancer in a patient.

18. The use of claim 17, ~~further comprising administering to the patient in need thereof~~ wherein the medicament is to be administered with a second therapeutic agent useful in the treatment of cancer.

19. The compound of claim 1, which is



20. The compound of claim 1, which is



21. The compound of claim 1, which is

